Compare SKYT & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKYT | TSHA |
|---|---|---|
| Founded | 1991 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2021 | 2020 |
| Metric | SKYT | TSHA |
|---|---|---|
| Price | $27.43 | $4.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $26.50 | $10.56 |
| AVG Volume (30 Days) | 872.7K | ★ 2.1M |
| Earning Date | 05-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1842.86 | 62.50 |
| EPS | ★ 2.44 | N/A |
| Revenue | ★ $442,139,000.00 | $8,333,000.00 |
| Revenue This Year | $40.53 | N/A |
| Revenue Next Year | $4.01 | N/A |
| P/E Ratio | $10.74 | ★ N/A |
| Revenue Growth | ★ 29.18 | N/A |
| 52 Week Low | $5.67 | $1.13 |
| 52 Week High | $36.07 | $6.02 |
| Indicator | SKYT | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 40.82 | 47.58 |
| Support Level | $14.54 | $4.41 |
| Resistance Level | $31.19 | $5.16 |
| Average True Range (ATR) | 1.07 | 0.20 |
| MACD | -0.24 | 0.00 |
| Stochastic Oscillator | 0.00 | 35.71 |
SkyWater Technology Inc is a U.S.-based, independent, pure-play technology foundry that offers semiconductor development and manufacturing services from its fabrication facilities. In its technology as a service model, it leverages a foundation of proprietary technology, engineering to co-develop process technology intellectual property (IP) with its customers that enable disruptive concepts through its Technology Services for diverse microelectronics (integrated circuits) and related micro- and nanotechnology applications. It focuses on serving diversified, high-growth, end users in numerous vertical markets, including computation, aerospace and defense (A&D), automotive and transportation, bio-health, and industrial.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.